Prevalence and related risk factors of chronic kidney disease among adults in Luxembourg: evidence from the observation of cardiovascular risk factors (ORISCAV-LUX) study

Ala’a Alkerwi 1*, Nicolas Sauvageot 1, Illiasse El Bahi 1, Charles Delagardelle 2, Jean Beissel 2, Stephanie Noppe 2, Paul J. Roderick 3, Jennifer S. Mindell 4 and Saverio Stranges 1, 5, 6

Abstract

Background: Evidence on stages of renal impairment and related risk factors in Luxembourg is lacking. This study aimed to assess the prevalence of chronic kidney disease (CKD) and identify potential correlates among the general population, using the recent definition suggested by the Kidney Disease Improving Global Outcomes guidelines.

Methods: Data analysed from 1361 participants aged 18–69 years, enrolled in the Observation of Cardiovascular Risk Factors in Luxembourg (ORISCAV-LUX) study, 2007–08. Descriptive and multivariable logistic regression analyses were performed to identify demographic, socio-economic, behavioural, and clinical factors associated with CKD, defined as a single estimated glomerular filtration rate (eGFR) measure <60 ml/min/1.73m² and/or urinary albumin:creatinine ratio (ACR) > 30 mg/g.

Results: Overall, 6.3% had CKD, including 4.4% and 0.7% with moderate and severe macroalbuminuria respectively. 0.1% had kidney failure (eGFR < 15 ml/min/1.73 m²). CKD was higher among subjects with primary education and risk increased significantly with age; the odd ratio was more than 2-fold higher among participants aged 50–69 years. Hypertension and diabetes were associated with more than 3-fold and 4-fold higher risks of CKD [adjusted odd ratio (AOR 3.46 (95%CI 1.92, 6.24), P < 0.001] and [AOR 4.45 (2.18, 9.07), P < 0.001] respectively. Increased physical activity measured as total MET-hour/week was independently associated with a lower odds of CKD (P = 0.035).

Conclusion: The national baseline prevalence estimate of CKD, a neglected public health problem, stresses the benefit of early detection particularly in high-risk subjects with associated cardiovascular pathologies (e.g. hypertension, diabetes), to prevent and defray costs related to eventual complications.

Keywords: Chronic kidney disease (CKD), Glomerular filtration rate, Albuminuria, Population-based study, Epidemiology

* Correspondence: alaa.alkerwi@lih.lu
1 Department of Population Health, Epidemiology and Public Health Research Unit, Luxembourg Institute of Health (LIH) (formerly CRP-Santé), Grand-Duchy of Luxembourg, 1A-B, rue Thomas Edison, L-1445 Strassen, Luxembourg
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
During the last decade, there has been a rising interest in the epidemiology of chronic kidney disease (CKD), which is now recognized as an important public health problem worldwide [1]. Patients with CKD are at high risk for progression to end stage renal disease (ESRD); a condition often requiring costly renal replacement therapy in the form of dialysis or transplantation. Although over 2 million people now require chronic renal replacement therapy worldwide [2, 3], only a minority of patients who are at risk for developing ESRD are under medical attention [4]. Moreover, CKD is associated with eight- to ten-fold increased risk of cardiovascular disease (CVD) mortality [5, 6]. Other complications include acute kidney injury, increased risk of infection, cognitive decline, anaemia, mineral and bone disorders and fractures [7].

The economic impact of CKD is enormous, whether related to direct healthcare cost or to indirect productivity lost with profound consequences on the quality of life of the individual, his family and society [3]. Recently, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) ranked low glomerular filtration rate (GFR) as the 12th leading risk factor for death at the global level, and the 14th risk factor for Disability-Adjusted Life-Years (DALYs) among 79 risk factors in 2013 [8]. In the past decade, attention has moved from treating only advanced stages of CKD toward prevention at earlier stages of CKD [4]. However, due to the asymptomatic nature of slowly progressing renal damage, CKD is frequently undetected until the very late stages, with few opportunities for prevention. Therefore, focusing efforts on early detection and treatment of CKD can prevent or delay progress to kidney failure or other adverse outcomes [9].

Low GFR has been identified among the top 10 leading cause of DALYs for both sexes in Luxembourg [10], where cardiovascular mortality accounts for about one-third of all deaths [11], and associated cardio metabolic pathologies, such as diabetes, hypertension, lipid disorders and obesity are demonstrably high [12, 13]. The objectives of this study were to provide baseline evidence on the prevalence of CKD among the general population in Luxembourg, to assess the different stages of CKD and identify potential socio-economic, clinical and behavioural correlates. Accurate assessment of CKD stages among the general population may provide important evidence-based information for policy makers and healthcare professionals regarding strategies for CKD prevention and healthcare planning.

Methods

Study design and participants
Analyses were based on data from the Observation of Cardiovascular Risk Factors in Luxembourg (ORISCAV-LUX) survey, a nationwide population-based cross-sectional study of adults in Luxembourg. A comprehensive description of the study design, sampling method, sample representativeness and data collection have been previously reported [12, 14]. Briefly, a stratified random sample of 1432 participants, aged 18–69 years, was recruited between November 2007 and January 2009, selected from the national insurance registry. For the present study, data from 1359 subjects were available for analyses, as 73 (5.1%) were excluded, because of missing blood samples to evaluate renal function.

Data collection and measurements
Participants self-reported their health status, socioeconomic status, personal and family medical histories and medication use. Information concerning their lifestyle factors (cigarette smoking, alcohol intake and physical activity) was collected by using Fagerström Test, Alcohol Use Disorder Test (AUDIT) and International Physical Activity Questionnaire (IPAQ), respectively. The IPAQ allowed to calculate total metabolic equivalent (METmin/week) for walking, moderate and vigorous physical activities [15]. The validated semi-quantitative FFQ [16, 17] was use to collect data on dietary habits. Participants recorded the frequency of consumption and portion size of 134 foods and beverages.

The clinical examination included measurements of height, weight, and blood pressure (BP). Systolic BP and diastolic BP (in mm Hg) were measured at least three times with a minimum 5-min interval, by using Omron® MX3 plus automated oscillometric Blood Pressure Monitor (O-HEM-742-E; Matsusaka, Japan). Participants were classified as hypertensive when the mean of the two last measurements was ≥140 mmHg systolic or ≥90 mmHg diastolic or when they reported taking anti-hypertensive medications.

Height and weight were measured by using a digital column scale (Seca 701; Hamburg Germany). BMI was calculated as weight in kg divided by height in m². Waist circumference (WC, cm) was measured at the level midway between the twelfth rib and the uppermost lateral border of the iliac crest during normal expiration. Obesity was defined as BMI ≥30 Kg/m².

Blood samples were drawn after an overnight 8-h fast and analysed at the national laboratory. Several parameters were assessed including liver enzymes (aspartate aminotransferase AST, alanine transaminase ALT and gammaglutamyl transpeptidase γGT, all in mg/dl), lipids (total cholesterol, triglycerides, high-density lipoprotein HDL and low-density lipoprotein LDL, all in mg/dl), glycaemic biomarkers (fasting plasma sugar FPG in mg/dl and haemoglobin A1c in %), high sensitivity C-reactive protein (hs-CRP; μg/l) and serum uric acid and creatinine (Cr) concentrations in mg/dl. For the assessment of Cr, an enzymatic method by Roche on a Cobas c501 instrument.
was used, which has calibration traceable to an isotope dilution mass spectrometry (IDMS) reference measurement procedure.

Renal function was evaluated by using estimated GFR (eGFR), based on the widely used 4-variable Modification of Diet in Renal Disease Study (MDRD) equation, as follows: eGFR = 175 × (serum Cr (mg/dl))^{-1.154} × age^{-0.203} × 0.742 for women × 1.21 if black, where GFR is expressed as ml/min/1.73 m^2 of body surface area, age in years and serum Cr is expressed in mg/dl [1, 18]. Then, eGFR were classified into stages 1–5, with stages 1 and 2 requiring the presence of kidney damage such as proteinuria as well as reduced eGFR to identify CKD [19].

Urine samples were collected as early morning, midstream urine specimens. Urinary albumin was assessed using the immunoturbidimetric assay Tinaquant Albumin Gen. 2 by Roche Diagnostics (Mannheim, Germany). Albumin: creatinine ratio (ACR in mg of albumin/g of creatinine) was determined as an early marker of glomerular injury and kidney damage. Abnormal levels were divided into macroalbuminuria (ACR >300 mg/g Cr) [20], which indicates advanced kidney disease and microalbuminuria (ACR ≥30 mg/g and <300 mg/g Cr) [19, 21], which indicates early-stage kidney disease, whereas ACR level of 0–29 mg/g Cr indicates non-clinically detected microalbuminuria.

**CKD and staging**

In the present study, subjects were classified as having CKD when eGFR was <60 ml/min/1.73m^2 (G3-G5), and/or ACR >30 mg/g Cr (level A2-A3) according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines [22, 23].

To permit an international comparison, we also presented the prevalence by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation as follows: GFR = 141 × min (s-Cr /κ, 1)^α × max(s-Cr /κ, 1)^-1.209 × 0.993^{0.026} × 1.018 [if female] × 1.159 [if black] [24], where: s-Cr is serum creatinine in mg/dl, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of s-Cr/κ or 1, and max indicates the maximum of s-Cr/κ or 1.

**Statistical analysis**

All statistical analyses were performed using the Statistical Package for the Social Sciences SPSS Statistics, Inc. version 24.0 software. Results were considered to be significant at the 5% level (P < 0.05). Initially, the prevalence of different stages of CKD were estimated and expressed as counts and proportions (%), by using both MDRD and CKD-EPI equations. To account for the stratified random sampling method, weighted statistical methods were applied to produce nationally representative CKD prevalence estimates. A sampling weight equal to the inverse probability of unit selection was allocated to each subject from the same stratum [14].

Then, descriptive analyses were performed to present demographic, socio-economic, behavioral, and cardio metabolic risk factors of participants with CKD, by using MDRD equation. Univariate logistic regression analyses were applied to identify the factors significantly associated with CKD prevalence. Results were expressed in terms of odds ratio (OR) and the respective 95% CI. For categorical variables, ‘low risk’ participants (younger age, women, Luxembourgers, tertiary level of education, living above poverty threshold, non-smokers, non-drinkers, physically active, absence of obesity, diabetes or hypertension, and without family history of selected medical conditions) were taken as reference categories.

Next, multivariable logistic regression analyses were performed to identify the independent contribution of socio-demographic, behavioral and biological factors to the risk of having CKD estimated by MDRD equation. Based on a literature review and on statistical criteria (variables showing P < 0.05 in the univariate analyses), the following variables were introduced in the multivariable model: age groups (18-49y; 50-69y), sex, education level (primary; secondary; tertiary), BMI, WC, HDL-cholesterol, serum triglycerides, serum ALT, hypertension (yes; no), diabetes (yes; no), and MET-hour/week for physical activity. To take account of medication intake, diabetes and hypertension were chosen rather than individual biomarkers such as FPG, HbA1c, systolic and diastolic BP. Obesity (yes; no) was not included in the multivariable model to avoid over-adjustment [25], likewise serum Cr as this variable is part of the eGFR formula. Concerning race, this “mainly Europid” study is underpowered to examine racial differences.

**Results**

**Prevalence of CKD**

Table 1 shows that 6.3% (89 participants) had CKD, where the eGFR estimated by MDRD, including 4.4% and 0.7% with moderate and severe albuminuria respectively, and 0.1% with kidney failure (eGFR < 15 ml/min/1.73 m^2).

By using CKD-EPI equation, the prevalence estimate was similar (5.9%; 82 subjects), with a difference of 7 cases which were not detected via this definition (Table 2).

**Factors associated with CKD**

Table 3 outlines the associations between a wide-range of demographic, behavioral and clinical characteristics of individuals with CKD, using the MDRD definition. Overall, the prevalence of CKD increased significantly with age; the odds ratio increased more than 2-fold among subjects aged 50–69 years. The distribution of CKD varied significantly according to education level; the frequency of CKD was higher among subjects with
primary education. There was no significant difference according to geographical district or country of birth. Among lifestyle factors, increased physical activity in MET-hour/week was associated with slightly, but statistically significantly, lower risk [odds ratio (95%CI): 0.97 (0.95, 0.99); \( P = 0.01 \)].

In univariate analyses, the prevalence of CKD differed substantially according to biochemical and clinical measurements, including BMI, WC, systolic and diastolic BP, FPG, glycated Hb, HDL-cholesterol, triglycerides and serum Cr (all \( P < 0.001 \)). Consequently, the prevalence estimates were significantly higher in the presence of obesity, hypertension, and diabetes and respective odd ratios were increased 3-fold, 4-fold, and 8-fold respectively (all \( P < 0.001 \)). Concerning dietary intake, there were no associations of CKD with salt, animal protein, meat, fruit or vegetable consumption.

In the multivariable analysis, increased physical activity remained independently correlated with lower odds of CKD [Adjusted Odds Ratio (AOR 0.97 (95%CI 0.95–0.99); \( P = 0.035 \)). Hypertension and diabetes were also independently associated with more than 3-fold and 4-fold higher risk of CKD [AOR 3.46 (1.92, 6.24); \( P < 0.001 \)] and [AOR 4.45 (2.18, 9.07); \( P < 0.001 \)], respectively (Table 4).

**Discussion**

CKD has been recognized as a worldwide public health problem due to rising prevalence, association with CVD mortality, poor outcomes, and dramatic complications which imply high costs and important burden on health care systems [19]. Renal epidemiology has blossomed in recent years, following several publications on renal impairment diagnosis and uniform clinical practice.

--

**Table 1** Identification of CKD estimated by MDRD, according to levels of eGFR and ACR categories, among 1359 participants in the Observation of Cardiovascular Risk Factors in Luxembourg (ORISCAV-LUX) study, 2007-08, aged 18–69 years

| eGFR and ACR categories and risk of adverse outcomes | ACR categories (mg/g Cr), description and range | GFR categories (ml/min/1.73 m²) | G1 | G2 | G3 | G4 | G5 | Total |
|------------------------------------------------------|-----------------------------------------------|---------------------------------|----|----|----|----|----|-------|
| <30 Normal to mildly increased                        | Normal to mildly increased                    | ≥90 Normal and high             | 612 (48.4%) [137,188] | 37 (2.8%) [7919] | 5 (0.3%) [940] | 654 (51.5%) [146,047] |
| 30–59.9 Mild reduction                                | Moderately increased                         | 658 (45.3%) [128,547] | 23 (1.6%) [4647] | 2 (0.1%) [356] | 683 (47.1%) [133,550] |
| 15–29.9 Severe impairment                             | Severe impairment                             | 17 (1.1%) [3125] | 0 | 2 (0.1%) [348] | 19 (1.2%) [3473] |
| <15 Kidney failure                                    | Kidney failure                                | 1 (0.1%) [194] | 0 | 1 (0.1%) [222] | 2 (0.1%) [416] |
| Total                                                |                                               | 1288 (94.9%) [269,054] | 60 (4.4%) [12,566] | 11 (0.7%) [2032] | 1359 (100%) [283,652] |

_Data represent number (%) of participants having the pathology [Estimated population in Luxembourg]. Sample weighting used to present data_ ACR albumin: creatinine ratio, CKD chronic kidney disease, GFR glomerular filtration rate

CKD identified in people with GFR <60 ml/min/1.73 m² (GFR categories G3-G5) or markers of kidney damage. In the absence of evidence of kidney damage such as albuminuria, neither eGFR category G1 nor G2 fulfil the criteria for CKD.

**Table 2** Identification of CKD estimated by CKD-EPI, according to levels of eGFR and ACR categories, among 1359 participants in the Observation of Cardiovascular Risk Factors in Luxembourg (ORISCAV-LUX) study, 2007-08, aged 18–69 years

| eGFR and ACR categories and risk of adverse outcomes | ACR categories (mg/g Cr), description and range | GFR categories (ml/min/1.73 m²) | G1 | G2 | G3 | G4 | G5 | Total |
|------------------------------------------------------|-----------------------------------------------|---------------------------------|----|----|----|----|----|-------|
| <30 Normal to mildly increased                        | Normal to mildly increased                    | ≥90 Normal and high             | 923 (70.5%) [199,875] | 48 (3.5%) [9983] | 6 (0.4%) [1119] | 977 (74.4%) [210,978] |
| 30–59.9 Mild reduction                                | Moderately increased                         | 354 (23.6%) [67,172] | 12 (0.9%) [2582] | 1 (0.1%) [178] | 367 (24.7%) [69,933] |
| 15–29.9 Severe impairment                             | Severe impairment                             | 10 (0.6%) [1812] | 0 | 2 (0.1%) [348] | 12 (0.8%) [2161] |
| <15 Kidney failure                                    | Kidney failure                                | 1 (0.1%) [194] | 0 | 1 (0.1%) [222] | 2 (0.1%) [416] |
| Total                                                |                                               | 1288 (94.9%) [269,054] | 60 (4.4%) [12,566] | 11 (0.7%) [2032] | 1359 (100%) [283,652] |

_Data represent number (%) of participants having the pathology [Estimated population in Luxembourg]. Sample weighting used to present data_ ACR albumin: creatinine ratio, CKD chronic kidney disease, GFR glomerular filtration rate

CKD identified in people with GFR <60 ml/min/1.73 m² (GFR categories G3-G5) or markers of kidney damage. In the absence of evidence of kidney damage such as albuminuria, neither eGFR category G1 nor G2 fulfil the criteria for CKD.
Table 3 Distribution of CKD according to demographic, socio-economic, behavioural and health-related characteristics of participants in ORISCAV-LUX study, 2007-08, aged 18–69 years

| Characteristics                     | n    | No CKD | CKD<sup>b</sup> | Crude OR | 95% CI | P-value |
|-------------------------------------|------|--------|-----------------|----------|--------|---------|
| **Socio-demographic characteristics** |      |        |                 |          |        |         |
| Age (years) Mean (SD)               | 1359 | 43.8 ± 0.36 | 49.47 ± 1.60 | 1.03     | (1.02–1.05) | <0.001  |
| N (%)                               | 1359 | N (%) | N (%) | 1 (Ref.) | <0.001 |
| 18–49                               | 855  | 67.3  | 41 (46.1) | 1 (Ref.) | <0.001 |
| 50–69                               | 415  | 32.7  | 48 (53.9) | 2.4      | (1.56–3.72) |
| **Sex**                             |      |        |                 |          |        |         |
| Female                              | 652  | 51.3  | 45 (50.6) | 1 (Ref.) |        |         |
| Male                                | 618  | 48.7  | 44 (49.4) | 1.03     | (0.67–1.58) |
| **Race**                            |      |        |                 |          |        |         |
| White                               | 1264 | 99.5% | 88 (98.9%) | 1 (Ref.) |        |         |
| Black                               | 6    | 0.5%  | 1 (1.1%)  | 0.41     | (0.05–3.51) |
| **Education level**                 |      |        |                 |          |        | 0.02    |
| Tertiary                            | 329  | 26.2  | 21 (23.6) | 1 (Ref.) |        |         |
| Secondary                           | 599  | 47.7  | 33 (37.1) | 0.86     | (0.49–1.51) |
| Primary                             | 328  | 26.1  | 35 (39.3) | 1.67     | (0.95–2.93) |
| **Country of birth**                |      |        |                 |          |        | 0.38    |
| Luxembourg                          | 762  | 60    | 53 (59.6) | 1 (Ref.) |        |         |
| Portugal                            | 147  | 11.6  | 15 (16.9) | 1.47     | (0.80–2.67) |
| Other European countries            | 77   | 6.1   | 3 (3.4)   | 0.91     | (0.52–1.58) |
| Non-European countries              | 284  | 22.4  | 18 (20.2) | 0.56     | (0.17–1.83) |
| **Geographical district**           |      |        |                 |          |        | 0.17    |
| Luxembourg                          | 926  | 72.9  | 72 (80.9) | 1 (Ref.) |        |         |
| Diekirch                            | 190  | 15    | 7 (7.9)   | 0.47     | (0.21–1.05) |
| Grevenmacher                        | 154  | 12.1  | 10 (11.2) | 0.83     | (0.42–1.65) |
| **Poverty threshold**               |      |        |                 |          |        | 0.29    |
| Above                               | 236  | 21.4  | 19 (26.8) | 1 (Ref.) |        |         |
| Below                               | 869  | 78.6  | 52 (73.2) | 1.34     | (0.78–2.32) |
| **Lifestyle factors**               |      |        |                 |          |        | 0.22    |
| Alcohol consumption                 |      |        |                 |          |        |         |
| Non-drinkers                        | 182  | 14.3  | 17 (19.1) | 1 (Ref.) |        |         |
| Drinkers                            | 1088 | 85.7  | 72 (80.9) | 0.71     | (0.41–1.23) |
| **Smoking status**                  |      |        |                 |          |        | 0.69    |
| Non-smokers                         | 990  | 78    | 71 (79.8) | 1 (Ref.) |        |         |
| Current smokers                     | 280  | 22    | 18 (20.2) | 0.9      | (0.53–1.53) |
| **Total MET-hour/week, Mean (SD)**  | 1294 | 13.62 | 10.58 (0.94) | 0.97     | (0.95–0.99) |
| **Biochemical and clinical measurements** |      |        |                 |          |        | 0.01    |
| BMI (Kg/m<sup>2</sup>)              | 1358 | 26.48 | 28.84 ± 0.66 | 1.09     | (1.04–1.13) |
| Waist circumference, cm             | 1358 | 89.47 | 96.19 ± 1.82 | 1.03     | (1.02–1.05) |
| Blood pressure, mm Hg               |      |        |                 |          |        |         |
| Systolic                            | 1357 | 129.08| 138.79 ± 2.42 | 1.03     | (1.02–1.04) |
| Diastolic                           | 1359 | 82.05 | 86.32 ± 1.39 | 1.03     | (1.02–1.05) |
| Pulse rate, beats/min               | 1359 | 68.87 | 70.89 ± 0.99 | 1.02     | (0.99–1.04) |
Table 3  Distribution of CKD according to demographic, socio-economic, behavioural and health-related characteristics of participants\(^a\) in ORISCAV-LUX study, 2007-08, aged 18–69 years (Continued)

| Characteristics                                      | n   | No CKD                        | CKD\(^b\)                       | Crude OR | 95% CI          | P-value |
|------------------------------------------------------|-----|-------------------------------|---------------------------------|----------|-----------------|---------|
| FPG, mg/dl                                           | 1330| 93.89 ± 0.44                  | 110.43 ± 4.39                   | 1.03     | (1.02–1.03)     | <0.001  |
| HbA1c, %                                             | 1330| 5.55 ± 0.01                   | 6.02 ± 0.11                     | 2.81     | (2.08–3.8)      | <0.001  |
| Serum total cholesterol, mg/dl                       | 1331| 201.35 ± 1.13                 | 196.78 ± 5.51                   | 1.00     | (0.99–1.00)     | 0.31    |
| Serum HDL cholesterol, mg/dl                         | 1331| 61.49 ± 0.48                  | 54.51 ± 1.86                    | 0.97     | (0.96–0.99)     | <0.001  |
| Serum LDL cholesterol, mg/dl                         | 1331| 124.36 ± 0.98                 | 121.4 ± 4.47                    | 0.998    | (0.99–1.00)     | 0.45    |
| Serum triglycerides, mg/dl                           | 1331| 113.07 ± 2.43                 | 162.89 ± 18.81                  | 1.00     | (1.00–1.00)     | <0.001  |
| Serum haemoglobin, mg/dl                             | 1358| 14.68 ± 0.037                 | 14.65 ± 0.17                    | 0.98     | (0.84–1.15)     | 0.83    |
| Serum creatinine, mg/dl                              | 1359| 0.83 ± 0.004                  | 0.94 ± 0.047                    | 10.45    | (3.47–31.45)    | <0.001  |
| Serum uric acid, mg/dl                               | 1359| 5.08 ± 0.038                  | 5.31 ± 0.17                     | 1.12     | (0.97–1.31)     | 0.13    |
| hs-CRP, μg/l                                          | 1359| 2.65 ± 0.13                   | 3.25 ± 0.44                     | 1.02     | (0.98–1.05)     | 0.26    |
| Serum ALT, mg/dl                                     | 1359| 25.39 ± 0.45                  | 29.56 ± 1.82                    | 1.01     | (1.00–1.02)     | 0.02    |
| Serum AST, mg/dl                                      | 1359| 22.54 ± 0.25                  | 23.1 ± 0.91                     | 1.01     | (0.98–1.03)     | 0.56    |
| Serum γGT, mg/dl                                      | 1359| 32.94 ± 1.22                  | 37.18 ± 3.17                    | 1.00     | (0.99–0.01)     | 0.37    |

Associated pathologies

| Hypertension\(^d\)                                    | 1358|                            |                                |          |                 | <0.001  |
|                                                      |     | N (%)                        | N (%)                          |          |                 |         |
| No                                                    | 816 (64.3) | 26 (29.2)                  | 1(Ref.)                        |          |                 |         |
| Yes                                                   | 453 (35.7) | 63 (70.8)                  | 4.36 (2.72–6.99)               |          |                 |         |
| Family history of HTA                                 | 1145|                            |                                | 0.93     |                 |         |
| No                                                    | 645 (60.3) | 44 (58.7)                  | 1(Ref.)                        |          |                 |         |
| Yes                                                   | 425 (39.7) | 31 (41.3)                  | 1.07 (0.66–1.72)               |          |                 |         |
| Diabetes mellitus\(^c\)                               | 1331|                            |                                | <0.001   |                 |         |
| No                                                    | 1196 (96.3) | 68 (77.4)                  | 1(Ref.)                        |          |                 |         |
| Yes                                                   | 46 (3.7)   | 21 (23.6)                  | 8.03 (4.54–14.21)              |          |                 |         |
| Family history of diabetes                            | 1287|                            |                                | 0.06     |                 |         |
| No                                                    | 938 (78)   | 58 (69)                     | 1(Ref.)                        |          |                 |         |
| Yes                                                   | 265 (22)   | 26 (31)                     | 1.59 (0.98–2.57)               |          |                 |         |
| Obesity                                               | 1358|                            |                                | <0.001   |                 |         |
| BMI <30 Kg/m\(^2\)                                    | 990 (78)   | 49 (55.1)                  | 1(Ref.)                        |          |                 |         |
| BMI ≥30 Kg/m\(^2\)                                    | 279 (22)   | 40 (44.9)                  | 2.9 (1.87–4.49)                |          |                 |         |

Dietary consumption

|                          |     | Mean (SD)                  | Mean (SD)                     |          |                 |         |
| Salt, mg/day             | 1270| 8.91 ± 0.11                | 8.79 ± 0.42                   | 0.99     | (0.94–1.05)     | 0.81    |
| Meat, mg/day             | 1282| 109.16 ± 2.44              | 112.84 ± 8.38                 | 1.00     | (0.99–1.00)     | 0.7     |
| Fruit & vegetables, g/day| 1278| 556.22 ± 11.47             | 608.34 ± 45.97                | 1.00     | (1.00–1.00)     | 0.25    |
| Animal protein, g/day    | 1267| 62.87 ± 0.83               | 63.74 ± 3.23                  | 1.00     | (0.99–0.03)     | 0.79    |

\(^{\text{FPG}}\) Fasting plasma glucose, \(^{\text{HbA1c}}\) glycated Hb, \(^{\text{WC}}\) waist circumference, \(^{\text{ALT}}\) Alanine transaminase, \(^{\text{AST}}\) Aspartate Aminotransferase, \(^{\text{γGT}}\) Gamma-glutamyl-transpeptidase

Data presented are means ± SE for continuous variables, otherwise numbers (%) for categorical variables

\(^{\text{a}}\) Difference in the number of cases is related to missing values for several variables

\(^{\text{b}}\) CKD estimated by MDRD equation

\(^{\text{c}}\) Participants were classified as having diabetes when serum glucose was 126 mg/dl or when they reported taking antidiabetic medications

\(^{\text{d}}\) Participants were classified as having HT when systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg and/or taking antihypertensive medications
guidelines. This is the first nationwide study to describe the epidemiology of CKD in Luxembourg, based on a standardized definition and staging of renal impairment, as suggested by the internationally accepted KDOQI guidelines [19, 22].

Our findings indicate that more than 6% of the general population in Luxembourg (representing >18,000 adults nationally) suffered from one of the 5 stages of renal impairment. Moreover, 0.7% (representing >2000 people) had severe macroalbuminuria (>300 mg/g Cr), and 0.1% had kidney failure. Normal individuals usually excrete very small amounts of protein in the urine. Persistently increased protein excretion is usually a sensitive marker of kidney damage. These findings flag a neglected public health issue in Luxembourg, which warrants national attention and further investigations.

These prevalence estimates were comparable to data from Lausanne city in Switzerland, where one in 10 adults suffers from CKD, based on similar diagnostic criteria [26]. Recent CKD Burden Consortium data suggests a substantial variation (from 3.3% to 17.3%) in CKD prevalence across Europe [27]. Based on earlier studies, a South-North gradient has been observed in CKD prevalence estimates, being higher in northeastern Italy (13.2%) [28] and Galician population in Spain (12.7%) [29] compared with Iceland (age-adjusted prevalence of low eGFR for adults, aged 35–80 years, was 4.7 and 11.6% for men and women, respectively) [30]. In the USA, 25 million people (about 12%) are estimated to have CKD, whereas only <0.2% (<500,000) have kidney failure treated by dialysis or transplantation [1, 31]. Similar prevalence estimates have been reported in Australia [32], and some reports note an increasing prevalence over time [33, 34]. Although our national CKD estimates are lower than the worldwide range (8–16%), [7] their public health burden is worsening with escalating CVD mortality and comorbidities, presenting substantial medical expenses.

Thus far, studies on CKD prevalence have been hampered by selection bias, or inappropriate detection criteria to define CKD stages [35]. Direct international comparisons is difficult due to important methodological differences regarding the setting of the target population, study design, as well as to the variety of CKD definitions used across different studies.

There are a number of potential factors that may have contributed to the relatively high prevalence of CKD among adults in Luxembourg. Consistent with previous reports [26], an elevated prevalence of CKD was observed in hypertensive (70.3%), diabetic (23.1%) and obese (44%) participants in the ORISCAV-LUX study. These conditions are highly prevalent in the Luxembourg population, as supported by our previous findings from ORISCAV-LUX study population [12]. The likelihood for CKD was significantly and independently increased by 3-fold and 4-fold in the presence of hypertension and diabetes, respectively. In addition, elevated serum triglycerides was substantially associated with higher odds for CKD. Evidence suggests that hypertension and diabetes are two major causes of kidney disease [36, 37]. As a complication, high BP may also develop early during the course of CKD and is associated with adverse outcomes, in particular, faster loss of kidney function and development of CVD [19].

### Table 4

Independent demographic, socio-economic, behavioural and health-related correlates to CKD as identified by multivariate logistic regression; in 1256 participants in the ORISCAV-LUX study, 2007-08, aged 18–69 years

| Covariates          | Categories                        | Adjusted OR (95% CI) | p-value |
|---------------------|-----------------------------------|----------------------|---------|
| Gender              | Male vs female                    | 0.52 (0.28–0.97)     | 0.041   |
| Educational Level   |                                    | 0.70 (0.38–1.29)     | 0.35    |
|                     | Primary v. tertiary                | 1.01 (0.53–1.92)     | 0.71    |
|                     | Secondary v. tertiary              | 0.97 (0.95–0.99)     | 0.009   |
|                    | 5 units increase                  | 0.95 (0.86–1.05)     | 0.35    |
|                    | 1 unit increase                   | 1.01 (0.97–1.05)     | 0.71    |
|                    | 1 mg/dl increase                  | 0.97 (0.95–0.99)     | 0.009   |
|                    | 1 mg/dl increase                  | 0.97 (0.98–1.01)     | 0.57    |
|                    | 1 mg/dl increase                  | 1.002 (1.00–1.004)   | 0.02    |
|                    | Hypertensive v. non-hypertensive   | 3.46 (1.92–6.24)     | <0.001  |
|                    | Diabetic v. non-diabetic subjects  | 4.45 (2.18–9.07)     | <0.001  |
|                    | 50–69 years v. 18–49 years        | 1.36 (0.79–2.35)     | 0.26    |

BMI: body mass index, WC: waist circumference, HDL: high-density lipoprotein cholesterol, ALT: Alanine transaminase.
kidney disease than in diabetic patients without kidney disease [19]. Recently, accumulated evidence indicates that the adverse outcomes of CKD can be prevented or delayed through therapeutic interventions during earlier stages, including blood glucose control in diabetic subjects, regular BP control, treatment with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, and dietary protein restriction. Because of the well-known interactions between CVD, hypertension, diabetes, and CKD, these findings have important clinical and public-health implications, in targeting these “high-risk” population subgroup of the population, who may benefit most from treatment to reduce progression and delay the onset of ESRD and cardiovascular complications [3, 38].

Increased physical activity was independently associated with lower odd for CKD. This association remained significant after further adjustment for demographic, socio-economic, and other lifestyle factors. From a public health standpoint, these findings may be interesting. Only a few population-based studies have reported this relationship [39, 40]; further prospective studies are needed to replicate this finding.

Strengths and limitations
This study is has several strong points. Our findings are based on a large nationwide, population-based sample of general adults in Luxembourg [12], showed to be comparable with the non-participants regarding demographic and clinical characteristics, hence reducing the potential selection bias [41]. Data weighting was applied to provide population-representative prevalence estimates. Kidney function was evaluated according to the most recent guidelines, based on a combination of eGFR which provides data on CKD stages, and urinary ACR which allows identification of 3 levels of microalbuminuria [4]. To estimate GFR, we applied the most widely used modified MDRD formula in clinical practice and epidemiological research, which accounts for the difference in assay methods by using correction factors [18, 42]. This formula is now being used for direct reporting of eGFR by our national laboratory in Luxembourg and other international laboratories to identify and monitor patients with reduced renal function [42]. To permit international comparison, prevalence estimates by CKD-EPI equation were presented and showed a minor difference. Additionally, the ORISCAV-LUX survey measured a large set of potential risk factors for CKD, including demographic, socio-economic, clinical, biological behavioural and dietary variables that have been rarely altogether investigated in similar studies.

Potential limitations include factors related to the cross-sectional design of the study which precludes inferences regarding causal relationships, single measures of eGFR and ACR due to unavailability of further samples to assess persistence pathology for ≥3 months; in addition to unavailability of data for participants older than 69 years, who have highest CKD prevalence estimates. Other shortcoming points include potential misclassification of albuminuria due to early- (not first-) morning sample; some statistically significant results may not be clinically significant due to low overall number of cases (89 with CKD), and extremely low numbers of person with higher-stage CKD (unstable estimates) with potential collinearity of variables.

CKD prevalence estimation is central to CKD management and prevention planning at the population level [27] and thereby help estimate the growing burden and demand for CKD services concomitant with aging population. We trust that our findings contribute to filling gaps on the worldwide atlas examining heterogeneities in CKD prevalence estimates. Such knowledge may provide an insight on recommendation to extend screening to people without diabetes or hypertension.

Conclusions
This is the first evidence-based report on the epidemiology of CKD in Luxembourg, highlighting that early preventive measures are needed to detect chronic kidney impairment and to reduce the incidence and mortality arising from the associated comorbidities. Given the burden of this public health problem [10], such data should guide national authorities and contribute to increase the awareness of scientific societies regarding the benefit of early detection of CKD, particularly in more susceptible and more disadvantaged groups. Earlier detection and appropriate management of CKD subjects will reduce cardiovascular events and slow further deterioration in renal function in these patients. These measures altogether could defray costs related to eventual ESRD development and higher risk of cardiovascular events.

Abbreviations
ACR: Albumin: creatinine ratio; ALT: Aspartate Aminotransferase; BMI: Body mass index; CKD: Chronic kidney disease; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; Cr: Creatinine; CVD: Cardiovascular disease; eGFR: Estimated glomerular filtration rate; HbA1c: Glycated Haemoglobin; hs CRP: High sensitivity C- reactive protein; KDIGO: Kidney Disease Improving Global Outcomes; KDOQI: National Kidney Foundation’s Kidney Disease Outcome Quality Initiative; MDRD: Modification of Diet in Renal Disease Study; OR: Odd ratio; ORISCAV-LUX: Observation of Cardiovascular Risk Factors in Luxembourg; SPSS: Statistical Package for the Social Sciences; WC: Waist circumference; γ-GT: Gamma-glutamyl-transpeptidase

Acknowledgements
Not applicable.
Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to ethical and legal reasons. In fact, we are not authorized to share our ORISCAV-LUX dataset with external researchers (another party, as this condition had not been requested in the informed consent signed by the participants in 2007–2008) but are available from the corresponding author on reasonable request.

Authors’ contributions
AA was involved in the conception and design of the ORISCAV-LUX survey, coordinated the field data collection, conceived the present research, contributed to the statistical analyses and drafted the first version of the manuscript. NS, IE performed statistical analyses and data interpretation. CD, JB, SN, PJR, JSM and SS. involved in revising the manuscript critically for important intellectual content. All authors approved the final version.

Ethics approval and consent to participate
The ORISCAV-LUX study was conducted according to the guidelines laid down in the Declaration of Helsinki. All procedures involving human subjects were approved by the National Research Ethics Committee “Comité National d’Ethique de Recherche- CNER” (N 2006/09/03) and the National Commission for Private Data Protection. Written informed consent was obtained from all subjects (copy available on need). This document has been written in line with our national legal authorities’ guidelines.

Consent for publication
Non-applicable. There was no strict separate « Consent for publication ». The participants however were informed about the following:

– I understand that my personal data will be treated in a strictly confidential way, as written in the amended law of 2nd August 2002 on the protection of individuals with regard on the processing of personal data.
– I understand that my data will be analysed in an anonymous manner by the LIPI and other international research organisations.
– I am aware that the publications related to this public health research will only concern scientific results and will never allow identifying participants.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Population Health, Epidemiology and Public Health Research Unit, Luxembourg Institute of Health (LIH) (formerly CRP-Santé), Grand-Duchy of Luxembourg, 1A-B, rue Thomas Edison, L-1445 Strassen, Luxembourg.
2Service of Cardiology, Centre Hospitalier du Luxembourg, Grand-Duchy of Luxembourg, Luxembourg, Luxembourg.
3Academic Unit of Primary Care and Population Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, South Academic Block, Tremona Road, Hampshire, Southampton SO16 6YD, UK.
4Research Department of Epidemiology & Public Health, UCL (University College London), London WC1E 6BT, UK.
5Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
6Department of Family Medicine, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.

Received: 14 June 2017 Accepted: 22 November 2017
Published online: 08 December 2017

References
1. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int. 2011;80(1):17–28.
2. Eggers PW. Has the incidence of end-stage renal disease in the USA and other countries stabilized? Curr Opin Nephrol Hypertens. 2011;20(3):241–5.
3. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major naccomunicable diseases. Kidney Int. 2011;80(12):1258–70.
4. de Jong PE, van der Velde M, Gansevoort RT, Zoccali C. Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol. 2008;3(2):66–23.
5. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371(9631):2173–82.
6. Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073–81.
7. Jha V, Garcia-Garcia G, Iseli K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013 Jul 20;382(9888):260–72.
8. Collaborators GRFS. Global, regional and national comparative risk assessment of 76 behavioural, environmental, occupational and metabolic risks or clusters of risks in 188 countries 1990–2013: a systematic analysis for the GBD 2013. Lancet. 2015;386(10010):2287–323. doi:10.1016/S0140-6736(15)00128-2. Epub 2015 Sep 11.
9. Locatelli F, Vecchio LD, Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol Dial Transplant. 2002;17(Suppl 11):2–7.
10. Collaborators GBDRF, Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, et al. Global, regional, and national comparative risk assessment of 76 behavioural, environmental, occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015; 386(10010):2287–323.
11. National Statistics of all causes of death, Statistiques des causes de décès. Luxembourg: Directorate of Health, Ministry of Health; 2015. http://www.sante.public.lu/fr/publications/s/statistiques-causes-deces-2015/index.html.
12. Alkerwi A, Sauvageot N, Donneau AF, Lair ML, Couffignal S, Beissel J, et al. First nationwide survey on cardiovascular risk factors in grand-duchy of Luxembourg (ORISCAV-LUX). BMC Public Health. 2010;10:468.
13. Alkerwi A, Donneau AF, Sauvageot N, Lair ML, Scheen A, Albert A, et al. Prevalence of the metabolic syndrome in Luxembourg according to the joint interim statement definition estimated from the ORISCAV-LUX study. BMC Public Health. 2011;11(1):34.
14. Alkerwi A, Sauvageot N, Couffignal S, Albert A, Lair ML, Guillaume M. Comparison of participants and non-participants to the ORISCAV-LUX population-based study on cardiovascular risk factors in Luxembourg. BMC Med Res Methodol. 2010;10:80.
15. IPAQ. Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ) – Short and Long Forms, revised on November 2005. Available: http://www.ipaq.ki.se/scoring.pdf. Accessed June 2017.
16. Sauvageot N, Alkerwi A, Adelin A, Guillaume M. Validation of the Food Frequency Questionnaire Used to Assess the Association between Dietary Habits and Cardiovascular Risk Factors in the NESCAV Study. J Nutr Food Sci 3:208. doi:10.4172/2155-9600.1000208.
17. Sauvageot N, Alkerwi A, Albert A, Guillaume M. Use of food frequency questionnaire to assess relationships between dietary habits and cardiovascular risk factors in NESCAV study: validation with biomarkers. Nutr J 2013;12(1):143.
18. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766–72.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1–266.
20. Verhave JC, Garrevoort RT, Hillegaert H, Bakker SJ, De Zeeuw D, de Jong PE, et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl. 2009;2(9):S178–21.

21. Kwak BO, Lee ST, Chung S, Kim KS. Microalbuminuria in normal Korean children. Yonsei Med J. 2011;52(3):476–81.

22. Stevens PE, Levin A. Kidney disease: improving global outcomes chronic kidney disease guideline development work group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(1):825–30.

23. Bauer C, Melamed ML, Hostetter TH. Staging of chronic kidney disease: time for a course correction. J Am Soc Nephrol. 2008;19(5):844–6.

24. Levey AS, Stevens LA, Schmid CH, Eggers P, Coresh J, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

25. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488–95.

26. Ponte B, Pruijm M, Marques-Vidal P, Martin PY, Burnier M, Paccard F, et al. Determinants and burden of chronic kidney disease in the population-based CoLaus study: a cross-sectional analysis. Nephrol Dial Transplant. 2013;28(9):2329–39.

27. Bruck K, Stel VS, Gambaro G, Hallan S, Vozzke H, Amlov J, et al. CKD prevalence varies across the European general population. J Am Soc Nephrol. 2016;27(7):2135–47.

28. Gambaro G, Yabarek T, Graziani MS, Gemelli A, Abaterusso C, Frigo AC, et al. Prevalence of CKD in northeastern Italy: results of the INCPE study and comparison with NHANES. Clin J Am Soc Nephrol. 2012;7(5):1946–53.

29. Otero A, Gayoso P, Garcia F, de Francisco AL, Group ES. Epidemiology of chronic renal disease in the Galician population: results of the pilot Spanish EPIRCE study. Kidney Int Suppl. 2005;99:S16–9.

30. Viktorsdottir O, Palsson R, Andresdottir MB, Aspelund T, Gudnason V, Indridason OS. Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults. Nephrol Dial Transplant. 2005;20(9):1799–807.

31. Coreosh J, Selvin E, Stevens LA, Manz J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.

32. Challan SJ, Britton EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol. 2003;14(7 Suppl 2):S131–8.

33. Hallan SI, Coresh J, Astor BC, Andersen M, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17(8):2275–84.

34. Imai E, Matsuo S. Chronic kidney disease in Asia. Lancet. 2008;371(9631):2147–8.

35. Noborisaka Y. Smoking and chronic kidney disease in healthy populations. Intern Med. 2013;52(9):604–12.

36. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003;14(11):2934–41.

37. Perneger TV, Brancati FL, Wheelon PK, Klag MJ. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med. 1994;121(12):912–8.

38. Hallan SI, Dahl K, Olend CR, Grootendorst DC, Aasberg A, Holmen J, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006;333(7577):1047.

39. Stengel B, Tuer V, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003;14(4):475–87.

40. Hallan S, de Munster R, Kirsen S, Dekker FW, Assarad K, Holmen J. Obesity, smoking, and physical inactivity as risk factors for CKD: are men more vulnerable? Am J Kidney Dis. 2006;47(3):396–405.

41. Alkerwi A, Sauvageot N, Buckley JD, Donneau AF, Albert A, Guillaume M, et al. The potential impact of animal protein intake on global and abdominal obesity: evidence from the observation of cardiovascular risk factors in Luxembourg (ORISCAV-LUX) study. Public Health Nutr. 2015;22:1–8.

42. Traynor J, Mactier R, Geddes CC, Fox JG. How to measure renal function in clinical practice. BMJ. 2006;333(7571):733–7.